Turn Therapeutics Inc.

Turn Therapeutics develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's primary focus is its lead program, GX-03, which is being studied for moderate-to-severe eczema. This research is based on preclinical evidence showing it can inhibit cytokines and reduce eczema severity, alongside a favorable real-world tolerability record from its prior use in cleared medical device indications. GX-03 is currently in an ongoing, randomized, double-blind, vehicle-controlled clinical study for moderate-to-severe eczema, with an interim assessment planned at approximately 50% trial completion. Topline results are expected mid-2026. In addition to eczema, GX-03 is being developed for onychomycosis, supported by in-vivo data demonstrating nail penetration and antifungal activity. The company's historical medical device portfolio, including K183681, K160872, and K171191, provides background tolerability and feasibility experience with the formula. K183681 has been licensed to Medline under a license and supply agreement. Turn Therapeutics is seeking new drug approvals for the GX-03 formula, which includes polyhexanide ("PHMB"), as a treatment for both eczema and onychomycosis. PHMB is a well-characterized polymer with strong antimicrobial, anti-inflammatory, and immunomodulating properties, and an established safety profile. The company also conducts exploratory work on a thermostable intranasal vaccine platform, but this is not part of its primary dermatology development path.